ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery

Biomed Pharmacother. 2020 Dec:132:110835. doi: 10.1016/j.biopha.2020.110835. Epub 2020 Oct 6.

Abstract

Bile acids has gradually become a new focus in various diseases, and ASBT as a transporter responsible for the reabsorption of ileal bile acids, is a key hinge associated to the bile acids-cholesterol balance and bile acids of enterohepatic circulation. The cumulative studies have also shown that ASBT is a promising target for treatment of liver, gallbladder, intestinal and metabolic diseases. This article briefly reviewed the process of bile acids enterohepatic circulation, as well as the regulations of ASBT expression, covering transcription factors, nuclear receptors and gut microbiota. In addition, the relationship between ASBT and various diseases were discussed in this paper. According to the structural classification of ASBT inhibitors, the research status of ASBT inhibitors and potential ASBT inhibitors of traditional Chinese medicine (such resveratrol, jatrorrhizine in Coptis chinensis) were summarized. This review provides a basis for the development of ASBT inhibitors and the treatment strategy of related diseases.

Keywords: ASBT; ASBT inhibitor; Bile acids metabolism; Enterohepatic circulation; Traditional Chinese medicine.

Publication types

  • Review

MeSH terms

  • Animals
  • Bile Acids and Salts / metabolism*
  • Cholesterol / metabolism*
  • Drug Development
  • Drug Discovery / methods
  • Humans
  • Ileum / metabolism
  • Medicine, Chinese Traditional
  • Organic Anion Transporters, Sodium-Dependent / antagonists & inhibitors*
  • Organic Anion Transporters, Sodium-Dependent / metabolism
  • Symporters / antagonists & inhibitors*
  • Symporters / metabolism

Substances

  • Bile Acids and Salts
  • Organic Anion Transporters, Sodium-Dependent
  • Symporters
  • sodium-bile acid cotransporter
  • Cholesterol